Hardcover: 382 pages
Publisher: Wiley-Liss (March 12, 2004)
ISBN: 0471225924
Product Dimensions: 10.4 x 7.1 x 0.9 inches

가격조정: 2004년 8월 11일 (한정판매가격임)
===========================================

Part I. Introduction.

1. At the Precarious Cusp of Oncogenomics (Charles Brenner).

Part II. Molecular Profiling in Cancer: DNA, RNA and Protein.

2. Genome-Wide Searches for Mutations in Human Cancer (Michael R. Stratton, P. Andrew Futreal, and Richard Wooster).

3. Molecular Cytogenetics: Increasing Resolution Using Array-Based CGH (Anne Kallioniemi).

4. SNPs and Functional Polymorphisms in Cancer (Penelope E. Bonnen and David L. Nelson).

5. Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility (Therese Sørlie, Anne-Lise Børresen-Dale, Per E. Lønning, Patrick O. Brown, and David Botstein).

6. Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays (Mary B. Daly, Alicia Parlanti, and David Duggan).

7. Linking Drugs and Genes: Pharmacogenomics, Pharmacoproteomics, Bioinformatics, and the NCI-60 (John N. Weinstein).

8. Tissue Microanalysis: Profiling Cancer Stages (Michael A. Tangrea and Michael R. Emmert-Buck).

9. Proteomic s in Bladder Cancer (Julio E. Celis, Irina Gromova, Fritz Rank and Pavel Gromov).

Part III. Model Systems.

10. Chemical and Genetic Methods to Validate Targets in Nonmammalian Organisms (Tia M. Maiolatesi and Charles Brenner).

11. Mouse Models of Cancer (Debrah M. Thompson, Louise van der Weyden, Patrick J. Biggs, Yeun-Jun Chung and Allan Bradley).

12. Genome-Wide Modifier Screens: How the Genetics of Cancer Penetrance May Shape the Future of Prevention and Treatment (Linda D. Siracusa, Karen A. Silverman, Revati Koratkar, Marina Markova and Arthur M. Buchberg).

Part IV. Molecularly Targeted Drugs.

13. Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches (Paul Nghiem, Yong-son Kim and Stuart L. Schreiber).

14. Ras Superfamily-Directed Compounds (George C. Prendergast).

15. Clinomics: Post-Genomic Cancer Care (Daniel D. Von Hoff, Haiyong Han, and David Bearss).

Part V. Conclusion).

16. Oncogenomics and the NCI Director's Vision for 2015 (Andrew C. von Eschenbach).